ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK) — Financial ratios
Profitability, liquidity, leverage, and valuation ratios for ImmuneOnco Biopharmaceuticals (Shanghai) Inc., with annual and quarterly history.
| Metric | 2025 |
|---|---|
| Valuation | |
| P/E Ratio | -10.27x |
| P/B Ratio | 2.73x |
| P/S Ratio | 14.37x |
| Profitability | |
| Gross Margin | 89.8% |
| Operating Margin | -144.6% |
| Net Margin | -141.7% |
| EBITDA Margin | -135.1% |
| Liquidity | |
| Current Ratio | 3.83x |
| Quick Ratio | 3.83x |
| Leverage | |
| Debt/Equity | 0.29x |
YoY = year-over-year change. Source: FMP..